GE Healthcare: Alzheimer Disease trials
The registry lists 10 Alzheimer Disease studies with GE Healthcare as lead sponsor. 1 are open to participants now and 8 have results posted.
Phase 2 3Phase 3 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Flutemetamol F 18 Injection Formulation ComparisonRecruitingNCT07873463Phase 2
- A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in EuropeCompletedNCT04773015Results posted
- Comparison of PET Amyloid Imaging in Japanese and Western SubjectsCompletedNCT02813070Phase 2Results posted
- Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) ImagesCompletedNCT01672827Phase 3Results posted
- Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult SubjectsCompletedNCT01265394Phase 3Results posted
- Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem LevelsCompletedNCT01165554Phase 3Results posted
- Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure HydrocephalusTerminatedNCT01092546Phase 3Results posted
- PET Imaging of Brain Amyloid in Normal Pressure HydrocephalusCompletedNCT01053312Phase 3Results posted
- Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's DiseaseCompletedNCT01028053Phase 3Results posted
- Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy VolunteersCompletedNCT00785759Phase 2